A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs
- PMID: 18279794
- DOI: 10.1016/j.intimp.2007.10.023
A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs
Abstract
Optimization of the use of monoclonal antibodies (MAbs) as diagnostic tools and therapeutic agents in the treatment of cancer is aided by quantitative characterization of the transport and tissue disposition of these agents in whole animals. This characterization may be effectively achieved by the application of physiologically based pharmacokinetic (PBPK) models. The purpose of this study was to develop a PBPK model to characterize the biodistribution of the pancarcinoma MAb CC49 IgG in normal and neoplastic tissues of nude mice, and to further apply the model to predict the disposition of multivalent single chain Fv (scFv) constructs in mice. Since MAbs are macromolecules, their transport is membrane-limited and a two-pore formalism is employed to describe their extravasation. The influence of binding of IgG to the protective neonatal Fc receptor (FcRn) on its disposition is also accounted for in the model. The model successfully described (131)I-CC49 IgG concentrations in blood, tumor and various organs/tissues in mice. Sensitivity analysis revealed the rate of transcapillary transport to be a critical determinant of antibody penetration and localization in the tumor. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. The model gave reasonably good predictions of the disposition of the scFv constructs. Since the model employs physiological parameters, it can be used to scale-up mouse biodistribution data to predict antibody distribution in humans. Therefore, the clinical utility of the model was tested with data for (131)I-CC49 obtained in patients, by scaling up murine parameter values according to known empirical relationships. The model gave satisfactory predictions of CC49 disposition and tumor uptake in man.
Similar articles
-
Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):264-73. doi: 10.1007/s00259-004-1664-0. Epub 2004 Oct 2. Eur J Nucl Med Mol Imaging. 2005. PMID: 15791435
-
The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.Nucl Med Biol. 2005 Feb;32(2):157-64. doi: 10.1016/j.nucmedbio.2004.11.003. Nucl Med Biol. 2005. PMID: 15721761
-
99mTc-Hydrazinonicotinamide-anti-TAG-72 CC49 tetravalent single-chain Fv monoclonal antibody.2007 Jun 26 [updated 2007 Dec 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jun 26 [updated 2007 Dec 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641718 Free Books & Documents. Review.
-
Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.Cancer Res. 2000 Dec 15;60(24):6964-71. Cancer Res. 2000. PMID: 11156397
-
Radioiodinated anti-TAG-72 CC49 tetravalent single-chain Fv antibody.2007 Jul 23 [updated 2008 Jan 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jul 23 [updated 2008 Jan 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641419 Free Books & Documents. Review.
Cited by
-
Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory.J Pharmacokinet Pharmacodyn. 2015 Apr;42(2):97-109. doi: 10.1007/s10928-014-9402-0. Epub 2015 Jan 11. J Pharmacokinet Pharmacodyn. 2015. PMID: 25577033
-
Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):125-39. doi: 10.1007/s10928-012-9243-7. Epub 2012 Mar 8. J Pharmacokinet Pharmacodyn. 2012. PMID: 22399130 Free PMC article.
-
Streamlining physiologically-based pharmacokinetic model design for intravenous delivery of nanoparticle drugs.CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):409-424. doi: 10.1002/psp4.12762. Epub 2022 Feb 7. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35045205 Free PMC article.
-
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.MAbs. 2016;8(2):229-45. doi: 10.1080/19420862.2015.1115937. Epub 2015 Dec 4. MAbs. 2016. PMID: 26636901 Free PMC article. Review.
-
Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide.In Silico Pharmacol. 2016 Dec;4(1):3. doi: 10.1186/s40203-016-0018-5. Epub 2016 Mar 1. In Silico Pharmacol. 2016. PMID: 26932471 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources